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ABSTRACT
Persistent infection is a key feature of hepatitis C virus (HCV). However, chimpanzee infections with cell culture-derived viruses
(JFH1 or related chimeric viruses that replicate efficiently in cell culture) have been limited to acute-transient infections with no
pathogenicity. Here, we report persistent infection with chronic hepatitis in a chimpanzee challenged with cell culture-derived
genotype 1a virus (H77S.2) containing 6 cell culture-adaptive mutations. Following acute-transient infection with a chimeric
H77/JFH1 virus (HJ3-5), intravenous (i.v.) challenge with 106 FFU H77S.2 virus resulted in immediate seroconversion and, fol-
lowing an unusual 4- to 6-week delay, persistent viremia accompanied by alanine aminotransferase (ALT) elevation, intrahepatic
innate immune responses, and diffuse hepatopathy. This first persistent infection with cell culture-produced HCV provided a
unique opportunity to assess evolution of cell culture-adapted virus in vivo. Synonymous and nonsynonymous nucleotide sub-
stitution rates were greatest during the first 8 weeks of infection. Of 6 cell culture-adaptive mutations in H77S.2, Q1067R (NS3)
had reverted to Q1067 and S2204I (NS5A) was replaced by T2204 within 8 weeks of infection. By 62 weeks, 4 of 6 mutations had
reverted to the wild-type sequence, and all reverted to the wild-type sequence by 194 weeks. The data suggest H77S.2 virus has
greater potential for persistence and pathogenicity than JFH1 and demonstrate both the capacity of a nonfit virus to persist for
weeks in the liver in the absence of detectable viremia as well as strong selective pressure against cell culture-adaptive mutations
in vivo.
IMPORTANCE
This study shows that mutations promoting the production of infectious genotype 1a HCV in cell culture have the opposite ef-
fect and attenuate replication in the liver of the only fully permissive animal species other than humans. It provides the only ex-
ample to date of persistent infection in a chimpanzee challenged with cell culture-produced virus and provides novel insight into
the forces shaping molecular evolution of that virus during 5 years of persistent infection. It demonstrates that a poorly fit virus
can replicate for weeks within the liver in the absence of detectable viremia, an observation that expands current concepts of
HCV pathogenesis and that is relevant to relapses observed with direct-acting antiviral therapies.
Persistent infections with human hepaciviruses are associatedwith chronic hepatic inflammation, progressive liver fibrosis,
cirrhosis, and hepatocellular carcinoma (1, 2). Worldwide, as
many as 200 million persons may be chronically infected with the
prototypical hepacivirus, hepatitis C virus (HCV). In the United
States, approximately 3.2 million persons are infected (3). Mor-
tality associated with HCV infections has increased significantly in
recent years, and it has exceeded that due to human immunode-
ficiency virus (HIV)/AIDS in the United States for almost a decade
(4). The high prevalence of HCV infection and strong association
with liver disease has engendered an intense effort to develop spe-
cific antiviral therapeutics targeting the virus, and recent results
from clinical trials suggest that many HCV infections can be com-
pletely cured with relatively brief therapy with all oral combina-
tions of small-molecule, direct-acting antiviral agents (DAAs) (5,
6). However, reinfection with reestablishment of persistent infec-
tion is clearly possible, and efforts to develop an effective HCV
vaccine have not met with similar success. Despite numerous
studies of both innate and adaptive immune responses and multiple
hypotheses (7, 8), there is no clear understanding of the primary
mechanism underlying the unique capacity of HCV to persist in
adult humans who are otherwise immunologically competent. In
large part, these gaps in current understanding of hepacivirus bi-
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ology can be attributed to the lack of a readily available, immuno-
competent small-animal model for hepatitis C, compounded by
limitations in the capacity of most human HCV strains to be prop-
agated in cell culture.
HCV is a positive-strand RNA virus classified within the family
Flaviviridae (genus Hepacivirus). It possesses a genome approxi-
mately 9.6 kb in length that encodes a total of 10 mature structural
and nonstructural proteins. Only a small number of cloned HCV
genomes (RNA transcribed from full-length cDNA molecular
clones) replicate efficiently in cell culture, and most of these con-
tain adaptive mutations that were selected in replicons under an-
tibiotic pressure (9–11). JFH1, a genotype 2a genome cloned from
the serum of a Japanese patient with fulminant hepatitis C, is
relatively unique in that it replicates with high efficiency in Huh-7
cells without the need for adaptive mutations (12, 13). HCV-N, a
genotype 1b genome cloned from a Japanese patient with chronic
hepatitis C, also replicates efficiently without adaptation to cell
culture (14, 15). However, it has an unusual 4-amino-acid inser-
tion in NS5A in proximity to cell culture-adaptive mutations doc-
umented in other cloned genomes. JFH1 and some chimeric ge-
nomes encoding JFH1 nonstructural proteins are also unique, in
that they produce substantial yields of infectious virus particles
when transfected into Huh-7 cells (12). These particles (JFH1) are
infectious for both naive Huh-7 cells as well as chimpanzees (Pan
troglodytes), the only animal species other than humans that is
fully permissive for HCV replication (12, 16). We have also doc-
umented the release of cell culture-infectious virus from Huh-7
cells transfected with a highly adapted genotype 1a viral genome
containing 5 cell culture-adaptive mutations (H77S) (17). The
titer of infectious virus released into supernatant fluids of H77S-
transfected cells was low compared to that of JFH1, but with mod-
ification of the adaptive mutations and optimized cell culture con-
ditions, it approaches or exceeds 104 focus-forming units (FFU) of
virus per ml (H77S.2 and H77S.3) (18). More recently, another
highly adapted genotype 1a genome, HCV-TNcc, has been shown
to produce cell culture-infectious virus with an efficiency rivaling
that of JFH1 (19). However, although JFH1 virus produced in cell
culture has been shown to be infectious in chimpanzees, this has
not been documented for either the H77S or HCV-TNcc virus.
Here, we report the serial challenge of a previously HCV-naive
chimpanzee with virus released into supernatant fluids by cells
transfected with H77S, an intergenotypic H77/JFH1 chimeric ge-
nome (HJ3-5) (20, 21), and H77S.2. As with all previously re-
ported chimpanzee infections with cell culture-produced viruses
containing the JFH1 replicase (Table 1), HJ3-5 infection was brief,
self-limited, and without demonstrable pathogenic effect. In con-
trast, subsequent challenge of this animal with H77S.2 virus led to
long-term, persistent infection with chronic hepatitis. We de-
scribe the evolution of the H77S.2 genome in this animal over a
period of 5 years, during which both the level of HCV viremia and
intrahepatic expression of interferon-stimulated genes (ISGs) in-
creased substantially and in parallel with the reversion of all 6
H77S.2 cell culture-adaptive mutations to their original wild-type
sequence. Thus, this study documents the induction of chronic
hepatitis C in a chimpanzee following inoculation of a cell culture-
derived virus. We also show that mutations that reduce replication
fitness can prevent detectable viremia for weeks despite ongoing
intrahepatic replication, a concept that is relevant to some antivi-
ral resistance-associated mutations and relapses after apparently
successful DAA therapy.
MATERIALS AND METHODS
Viruses and plasmids. The plasmid pH77S contains the full-length geno-
type 1a H77c virus sequence (22) with the addition of 5 cell culture-
adaptive mutations and has been described previously (17). pH77S.2 is
derived from it and includes a sixth cell culture-adaptive mutation,
N476D (AAC¡GAC). pH77S.3 is derived from pH77S.2 and was created
by removal of the Q1067R adaptive mutation in NS3 (18). The chimeric
infectious molecular clone, pHJ3-5, is comprised of the structural pro-
tein-coding region of H77c virus placed within the background of the
genotype 2a JFH1 virus, with adaptive mutations in E1 (Y361H) and NS3
(Q1251L) (20). Viruses were produced by transfection of Huh-7 or Huh-
7.5 (23) cells by electroporation of synthetic RNA transcribed from these
plasmids, as described previously (17, 18).
Inoculum preparation. Supernatant fluids from RNA-transfected
cell cultures were passed through a 0.45-m-pore-sized filter and then
concentrated approximately 10-fold using a Centricon Plus-70 centrifu-
gal filter unit with an Ultracel-PL membrane (100-kDa exclusion;
UFC710008; Millipore). Bacterial sterility was confirmed prior to inocu-
lation. The final cell culture-infectious virus titer was determined by an
infectious fluorescent focus (FFU) assay (17).
Chimpanzee infections. A single, adult, female, HCV- and human
immunodeficiency virus-naive chimpanzee (4x0193) was challenged se-
quentially with 3 successive cell culture-produced virus preparations,
each inoculated intravenously as described in Results. This animal ex-
pressed Patr class I A and B alleles A*0201, A*0301, B*0101, and B*1301,
determined by sequence-based genotyping as described previously (24).
The chimpanzee was housed and cared for at the Southwest National
Primate Research Center (SNPRC) of the Texas Biomedical Research In-
stitute in accordance with the Guide for the Care and Use of Laboratory
Animals. The study protocol was approved by the Institutional Animal
Care and Use Committee of the Texas Biomedical Research Institute (for-
merly the Southwest Foundation for Biomedical Research). The SNPRC is
accredited by the Association for Assessment and Accreditation of Labo-
ratory Animal Care (AAALAC) International and operates in accordance
with the NIH and U.S. Department of Agriculture guidelines and the
Animal Welfare Act. All experimental manipulations of this animal were
completed prior to the release of a report from the Institute of Medicine
on the use of chimpanzees in biomedical research (25) and its acceptance
by the National Institutes of Health on 15 December 2011.














x0483 FL-J6/JFH1 106 TCID50 1–15 2 2  10
4 No 10 50
x0495 FL-J6/JFH1 106 TCID50 1–6, 15 2 7  10
4 No 13 50
x0215 JFH1 8.0  106 GE 2–5 4 2 103 No No 12
10274 JFH1 9.6  106 GE 2–8 4 1 103 No No 16
4x0193 HJ3-5 106 FFU 1–3 1 1 104 No Noa This report
a The increase in OD did not reach the threshold for a positive result.
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HCV RNA detection. HCV RNA levels were monitored in chimpan-
zee serum and liver biopsy specimens by real-time, quantitative reverse
transcription-PCR (qRT-PCR) (TaqMan), as described previously (26).
More sensitive, nonquantitative detection of HCV RNA was performed
using a transcription-mediated amplification assay (TMA). The Versant
HCV RNA qualitative TMA assay amplifies conserved regions within the
5=-untranslated region (UTR) of the hepatitis C viral genome and has a
sensitivity of 7.5 IU/ml (Siemens Clinical Laboratory, Berkley CA).
Anti-HCV ELISA. Serum samples were monitored for antibody re-
sponse to HCV proteins by ELISA (enzyme-linked immunosorbent assay)
using the Ortho 3.0 HCV test (Ortho Diagnostic Systems, Raritan, NJ).
HCV neutralization assays. Neutralizing antibodies to genotype 1a
H77 virus were quantified using an FFU reduction assay as described
previously (27).
qRT-PCR quantitation of ISG transcripts. Interferon and interferon-
stimulated gene (ISG) transcript abundance in liver biopsy specimens was
determined by qRT-PCR (TaqMan). Total RNA was prepared using RNA
Bee extraction (AMS Biotechnology, Ltd.), a guanidinium HCl phenol-
based extraction procedure, with isopropanol precipitation. Total RNA
was quantified using a Nanodrop spectrophotometer, and RNA quality
was verified by the ratio of the optical density at 260 nm (OD260) to that at
280 nm (i.e., the OD260/280 ratio) or by an Experion automated microflu-
idics system for analysis of RNA (Bio-Rad). The high homology existing
between chimpanzee and human genomes (28) enabled use of human
RT-PCR Assays-on-Demand primers (Applied Biosystems).
Immunohistochemistry. Antigen retrieval and immunohistochemi-
cal staining of liver biopsy sections for ISG-15, activated caspase 3, and the
proliferation marker Ki-67 were carried out as described previously (29).
Cytokine and chemokine analysis. Monitoring of 16 cytokines and
chemokines was performed by the SNPRC Immunology Core using
Luminex100 with the xMAP multianalyte platform and a customized
panel optimized for cross-reactivity to primate samples.
HCV RNA sequence determination. HCV RNA was extracted from
serum with the ViraRNA Minikit (Qiagen) and then reverse transcribed to
cDNA with the SuperScript III first-strand synthesis system for RT-PCR
kit (Invitrogen) and random hexamers by following the manufacturer’s
suggested protocol. Overlapping segments of the HCV genome were am-
plified by nested PCR, using 2 l undiluted cDNA as the template for the
first round of PCR in a 10-l reaction mix and 1 l undiluted first-round
PCR product as the template for the second round of PCR in a 50-l
reaction mix and reagents provided with the PrimeSTAR HS (Premix) kit
(TaKaRa) with a two-step PCR protocol (98°C for 10 s, 68°C for 2 min).
PCR products were purified from a 1% agarose gel using a gel extraction
kit (Qiagen) and sequenced directly with HCV-specific primers. Rates of
nonsynonymous substitutions per nonsynonymous site (dN) and synon-
ymous substitutions per synonymous site (dS) were calculated by the
method of Nei and Gojobori (30) using the Codon Suite server (http:
//www.cbrg.ethz.ch/services/CodonSuite).
Reverse molecular genetics experiments. Selected nucleotide substi-
tutions identified in virus from serum collected 8 weeks after inoculation
of H77S.2 were introduced into pH77S.2 using the QuikChange II XL
site-directed mutagenesis kit (Stratagene). The correct insertion of the
substitution and absence of other changes within the manipulated seg-
ments of the plasmid were verified by DNA sequencing. RNA was tran-
scribed from the plasmid and electroporated into FT3-7 cells as described
previously (20). Replication was assessed by real-time quantitative RT-
PCR measurement of HCV RNA and FFU assay for release of cell culture-
infectious virus (17).
Informatics analysis of amino acid substitutions in HCV nonstruc-
tural proteins. Protein structures were retrieved from the RCSB Protein
Databank (PDB) (http://www.rcsb.org/pdb/home/home.do): PDB entry
1CU1 (31) for the NS3 protease-helicase, PDB entries 3FQQ (32) and
1ZH1 (33) for NS5A domain I, and PDB entry 2XI2 (34) for the NS5B
polymerase. ProMate, a structure-based prediction program running on
the ProMate server (http://bioinfo.weizmann.ac.il/promate/) (35), was
used to calculate the probability that protein residues altered by nonsyn-
onymous nucleotide substitutions contribute to protein-protein interac-
tion sites. Predictions were carried out with the standard configuration.
The algorithm predicts unknown protein-protein interaction sites based
on knowledge of the properties of known protein-binding sites, including
physicochemical properties, bound versus unbound water molecules, and
the B-factor reflecting the relative dynamic motion, all derived from a
database of proteins with known protein-protein interactions. The
PyMOL Molecular Graphics System (http://www.pymol.org; DeLano Sci-
entific, San Carlos, CA, USA) with Color B script (http://pldserver1
.biochem.queensu.ca/rlc/work/pymol/) was used to project ProMate
output onto the surfaces of the NS3, NS5A, and NS5B structures, respec-
tively. WHAT IF was used to compute the solvent accessibilities (in Å2) of
residues in the structural models of NS3, NS5A domain I, and NS5B
(described above). The solvent accessibilities of residues affected by non-
synonymous substitutions were then compared to those of all residues in
each structural model. P values were calculated using the nonparametric
Mann-Whitney U test.
Alb-uPa/SCID mouse studies. Mice were transplanted as previously
described with human hepatocytes purchased from Invitrogen (36, 37).
Mice with human albumin levels greater than 2 mg/ml were infected with
either 1.5  105 FFU of H77S.3 virus injected intraperitoneally or 240 g
of genomic RNA encoding H77c, H77S, H77S.2, H77S.2/I2204T, H77S.3,
and H77S.3/I2204T viruses injected intrahepatically. Blood was drawn
weekly, and serum HCV RNA levels were determined as described previ-
ously (37). All mice were housed and treated according the Canadian
Council on Animal Care guidelines, with experimental approval from the
University of Alberta Animal Welfare Committee.
RESULTS
H77S virus challenge in chimpanzee 4x0193. The original cell
culture-adapted genotype 1a H77S clone contains 5 cell culture-
adaptive mutations located in NS3, NS4A, and NS5A (17). Cells
transfected with synthetic H77S RNA release virus into superna-
tant culture fluid that has a buoyant density of 1.13 gm/cm3 and
is capable of infecting naive Huh-7.5 cells (102 to 103 FFU/ml). To
determine whether this virus was infectious in the chimpanzee, we
concentrated H77S virus from supernatant fluids by centrifugal
filtration. A sterile 10-ml suspension containing 104 FFU H77S
virus was inoculated intravenously into a 25-year-old, previously
HCV-naive female chimpanzee (4x0193). Subsequent monitoring
of the animal over a period of 28 weeks revealed an isolated in-
crease in serum alanine aminotransferase (ALT) from a baseline of
30  5.9 U/liter (means  standard deviations [SD]) to 88 U/liter
3 weeks postinoculation but no evidence of HCV viremia or anti-
HCV seroconversion (ELISA or anti-HCV neutralization) (Fig.
1A). The results led us to conclude that the H77S inoculum did
not contain sufficient chimpanzee-infectious virus to initiate an
infection.
HJ3-5 virus challenge. To document the susceptibility of
4x0193 to HCV infection and also assess the infectivity of a chi-
meric H77/JFH1 virus produced in cell culture, the animal was
inoculated intravenously with 106 FFU HJ3-5 virus 32 weeks after
the initial H77S virus challenge. The HJ3-5 genome is comprised
of H77S RNA encoding the core-to-NS2 segment of the polypro-
tein placed within the JFH1 background (21). It contains adaptive
mutations in E1 (Y361H) and NS3 (Q1251L) that promote its
replication and facilitate the production of infectious virus in cell
culture at yields that are approximately 100-fold higher than those
of the original JFH1 cDNA clone (20). The animal became viremic
within 1 week of inoculation (1.1 104 GE/ml) and remained so
for the ensuing 3 weeks (Fig. 1A and B). HJ3-5 virus was isolated
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from week 1 and week 3 postinoculation sera in Huh-7.5 cells,
with discrete foci of replication detected by immunofluorescence
for HCV core antigen within 4 days of inoculation with week 1
serum and 11 days with week 3 serum (data not shown). By 4
weeks after inoculation, viremia had declined to a level no longer
detectable by conventional real-time qRT-PCR but was still evi-
dent in a sensitive, qualitative transcription-mediated amplifica-
tion (TMA) assay (sensitivity, 7.5 IU/ml). Repeat serum TMA
assays were negative 16 and 51 weeks after inoculation of HJ3-5
virus. Reactivity in the anti-HCV ELISA rose from a preinocula-
tion baseline OD of 0.039  0.019 (means  SD) to a peak of 0.247
at week 16 and then declined to baseline, never reaching the
threshold for seroconversion (Fig. 1B). Neutralizing antibodies
were not detected by an FFU reduction assay at 6 and 34 weeks
after challenge, despite the brief period of viremia. Maximum se-
rum ALT was 43, just 2 standard deviations above baseline, at 3
weeks (Fig. 1B). Collectively, these results indicate that HJ3-5 vi-
rus produced in cell culture is infectious in the chimpanzee, but
that it engenders little serological response. Like other cell culture-
derived HCVs containing the JFH1 replicase that have been stud-
ied in chimpanzees (Table 1), HJ3-5 virus caused only an acute
transient infection without persistence of virus or evidence of sig-
nificant liver injury.
Viral RNA present in sera collected from 4x0193 at 1 and 3
weeks after inoculation of HJ3-5 virus was extracted, converted to
cDNA, amplified by RT-PCR, and sequenced to confirm that the
circulating virus was HJ3-5. Both cell culture-adaptive mutations
were present in the week 1 virus, and the Q1251L mutation re-
mained present at week 3. Sequence could not be obtained to
confirm the continuing presence of Y361H in week 3 sera, but it
was present in virus isolated in cell culture from this sample (data
not shown). Thus, there appeared to be no selective pressure
against these adaptive mutations in HJ3-5 during replication in
the chimpanzee. Several new substitutions were identified in the
NS2 and NS3 regions of the circulating virus, including nonsyn-
onymous substitutions in NS2 and the protease domain of NS3
(Table 2).
H77S.2 challenge. Two years (108 weeks) after the initial chal-
lenge of 4x0193 with 104 FFU H77S virus (76 weeks after HJ3-5
challenge), 4x0193 was rechallenged intravenously with 106 FFU
of H77S.2 virus, also produced in cell culture. H77S.2 virus differs
from H77S by the presence of an Asn-to-Asp substitution at resi-
due 476 (E2 protein) that results in a reproducible 2- to 4-fold
increase (means, 3.1; standard errors of the means [SEM], 0.41) in
the titer of infectious virus released by RNA-transfected Huh-7
cells (Fig. 2A) without influencing the kinetics of RNA replication
(Fig. 2B). The mutation was identified originally in an intergeno-
typic chimeric HCV RNA, H77-(NS2)-JFH1 (21). Despite prob-
able immunologic priming of 4x0193 by the preceding HJ3-5 in-
fection, this third infectious challenge with a high-titer H77S.2
inoculum resulted in a sustained, persistent infection associated
with evidence of significant liver injury. However, the course of
the infection was unusual in several respects.
First, although both ELISA and neutralizing antibody (FFU
reduction) assays were negative for anti-HCV at the time of
H77S.2 challenge, the ELISA was positive 1 week later (Fig. 1C).
Consistent with an anamnestic response, the serum neutralizing
antibody titer rose from nondetectable at the time of inoculation
FIG 1 Serial challenge of chimpanzee 4x0193 with cell culture-derived HCVs. (A) Virologic markers (serum and intrahepatic HCV RNA and ELISA detection
of anti-HCV) and serum ALT activity over a 290-week period. Viruses were inoculated intravenously at the time shown from the nominal week 0 for each;
intervening gaps in time are not to scale (see the text for details). Horizontal dotted lines indicate baseline ALT activity (means  2 SD). (B) Expanded view of
the 40 weeks following inoculation of HJ3-5 virus (second infectious challenge, 106 FFU). The results of transcription-mediated amplification (TMA) assays
for detection of HCV RNA in serum and FFU reduction assays for detection of neutralizing antibody (nAb) to HCV (H77 envelope) are shown at the top. (C)
Similar expanded view of the 40 weeks following challenge with H77S.2 virus (third infectious challenge, 106 FFU). Note that the liver biopsy specimen taken
at 2 weeks after H77S.2 inoculation contained low levels of HCV RNA.
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to 1:80 at week 2. Despite this, there was no detectable viremia
until week 4, when the very sensitive TMA assay first detected the
presence of HCV RNA; the standard qRT-PCR assay became pos-
itive at 1.36 103 GE/ml 1 week later (Fig. 1C). Notably, however,
a very low level of HCV RNA, resulting in erratic detection in
repeat assays, was present in a liver biopsy specimen taken at week
2, when the serum TMA was negative. Following its first appear-
ance in the serum at week 4, the magnitude of viremia increased
rapidly, peaking at 1.39  104 GE/ml at week 12 and then dipping
to 1.85  103 GE/ml at week 26 before beginning a slow, sustained
rise to 105 to 106 GE/ml by 250 to 288 weeks (5.5 years) (Fig. 1A).
Thus, the course of H77S.2 infection in 4x0193 was marked by an
initial 4-week period of very low-level replication in the liver in the
absence of detectable viremia, followed by the apparent emer-
gence of viral variants with greater replicative fitness (described
below).
Despite the presence of intrahepatic viral RNA and slight in-
creases in serum ALT (54 and 48 U/liter at 1 and 2 weeks postin-
oculation, respectively) (Fig. 1C), histopathologic changes in the
liver were confined to minimal hepatocellular cytoplasmic swell-
ing (Fig. 3A, compare preinfection to week 2). Following the ap-
pearance of viremia, however, the serum ALT activity became
substantially increased (peaking at 114 U/liter) and remained well
above the baseline subsequently (Fig. 1A). This was associated
with a minimal increase in periportal lymphoid infiltrates by week
8 that were notably increased on subsequent liver biopsy speci-
mens at week 194 (Fig. 3A). Remarkably, Masson trichrome stains
of liver tissue demonstrated significant hepatic fibrosis at 194
weeks, particularly in and around portal triads (Fig. 3B). However,
while collagen deposition was clearly increased from the preinfec-
tion biopsy specimen, there was no bridging fibrosis. There was
also an increase in caspase 3-positive cells, many observed within
inflammatory infiltrates, and greater numbers of Ki67-positive
cells undergoing proliferation (Fig. 4). Interferon-stimulated gene
15 (ISG-15) expression was evident within hepatocytes by immu-
nohistochemistry as early as 8 weeks postinfection (Fig. 5A, top),
although mRNA transcripts for it and other ISGs (IP-10, CXCL11,
CXCL9, and IFIT1) were not detectably elevated within the liver
until week 26 (Fig. 5B). Despite hepatocellular ISG-15 expression
being markedly increased by 194 weeks (Fig. 5A and B), only min-
imal increases in type I and III interferon (IFN- and IFN-2/3)
and IFN-	 transcripts were detected at the latter time point (Fig.
5C). Proinflammatory cytokine expression also became promi-
TABLE 2 Changes in HJ3-5 virus sequence during acute transient infection in chimpanzee 4x0193e
Adaptive mutation





1 3 1 3
TAT¡CAT, Y361H 1422 NDb E1 361 ND
2570 A¡G A¡G
3122 G¡U G¡U NS2 927 K¡N K¡N
3870d G¡A NS3pc 1177a R¡K
CAT¡CUG, Q1251L 4092d NS3h 1251a
a Virus in week 1 serum was sequenced between nt 250 and 5113, and virus from week 3 serum was sequenced between nt 1880 and 5113 only.
b ND, not determined.
c NS3p, protease domain; NS3h, helicase domain.
d Numbered according to the JFH1 sequence.
e Cell culture-adaptive mutations and reversions are shown in boldface; synonymous nucleotide substitutions are shaded. nt, nucleotide; aa, amino acid.
FIG 2 Impact of cell culture-adaptive mutations and reversions on viral rep-
lication in Huh-7.5 cells. (A) Infectious virus released by cells 2 days after
transfection with the indicated HCV RNA. Values shown represent the
means  SD of 2 (H77S) or 4 (all others) FFU assays from two independent
experiments. An asterisk indicates P 
 0.03 for the difference in yield from
H77S.2 by two-sided Mann-Whitney test. (B) qRT-PCR analysis of the fold
increase in H77S versus H77S.2 RNA relative to H77S/AAG RNA (lethal
NS5B mutant) following transfection of Huh-7.5 cells. (C) Fold increase of
H77S.2 mutant RNAs, as described for panel B. (D) Immunofluorescence
detection of HCV core protein in cells transfected with H77S.2 versus
H77S.2/12204T RNA.
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nent following the appearance of viremia. Serum interleukin-12
(IL-12), IP-10, and MIP-1 protein levels, all of which became
markedly elevated at the termination of HJ3-5 viremia, became
reelevated with the appearance of H77S.2 RNA in the serum, con-
sistent with a resurgent cellular immune response (Fig. 5A, top).
In contrast, serum levels of the inflammasome-related cytokines
IL-1 and IL-18 increased immediately after H77S.2 inoculation
but did not track closely with HCV viremia or ALT activity (Fig.
5A, bottom). They may have represented a nonspecific response to
contaminating cellular antigens in the inoculum.
Evolution of the H77S.2 genome during persistence in
4x0193. The persistence of H77S.2 virus in animal 4x0193 pro-
vided a unique opportunity to characterize the evolution of a cell
culture-adapted HCV genome in vivo. We determined the se-
quence of all but the extreme 5= end of the H77S.2 genome from
serum samples collected at weeks 8, 62, 194, and 250. Numerous
synonymous and nonsynonymous nucleotide substitutions were
evident as early as 8 weeks (Fig. 6), including changes in 2 of the 6
cell culture-adaptive mutations: reversion of Q1067R (NS3 pro-
tease) to the wild-type Gln and a change in S2204I (NS5A) to Thr
(Table 3). This S2204T mutation was also present in a small frag-
ment of RNA amplified from the liver at week 2. These changes
were accompanied by several other nonsynonymous substitutions
in the NS3 sequence of circulating virus at week 8 and multiple
additional substitutions throughout the genome by week 62. Rates
for both synonymous and nonsynonymous substitutions, esti-
mated according to the method of Nei and Gojobori (30), de-
clined progressively over time (Fig. 6B); the ratio of nonsynony-
mous substitutions per site to synonymous substitutions per site
(dN/dS) fell from 0.50 during the first 62 weeks of infection to
0.18 by week 194 (Fig. 6C). By week 62, the original S2204I
adaptive mutation had fully reverted to the wild-type Ser, and two
other adaptive mutations, N476D and K1691R, had also reverted
to the wild-type H77c sequence. By week 194, all 6 of the cell
culture-adaptive mutations had reverted to the original amino
acid sequence (Table 4). The reversion of adaptive mutations and
decreasing rates of both synonymous and nonsynonymous sub-
stitutions elsewhere in the genome correlated with progressive
increases in the level of viremia (Fig. 6B).
The 4- to 6-week delay in appearance of H77S.2 viremia (Fig.
1C) coupled with the onset of viremia only after loss of adaptive
mutations at Q1067 and S2204 strongly suggests that these muta-
tions compromise in vivo viral fitness despite promoting replica-
tion in Huh-7 cells. This has been reported previously for muta-
tions facilitating replication of a genotype 1b RNA replicon in cell
culture (38). To better understand the significance of the change
from Ile to Thr at residue 2204 that we documented at 8 weeks in
4x0193 (Table 3), we introduced this mutation into the H77S.2
genome. Interestingly, despite being associated with the appear-
ance of viremia in the chimpanzee, the resulting RNA (H77S.2/
I2204T) was substantially handicapped in its ability to replicate in
transfected FT3-7 cells compared to H77S.2, with an approximate
FIG 3 Liver histopathology in chimpanzee 4x0193. (A) Hematoxylin and
eosin-stained sections of tissue collected prior to and following infection with
H77S.2 virus. Mild hepatocellular swelling with minimal impingement of
hepatic sinuses and disruption of cords is evident at 2 weeks postinoculation of
virus. Following the appearance of viremia, 8 weeks after inoculation, there
was moderate hepatocellular swelling with increased impingement of sinuses.
Minimal lymphocyte infiltration was evident in portal regions. By 194 weeks,
the hepatic cords had become disorganized and the sinusoidal spaces markedly
narrowed. Periportal mononuclear cell infiltrates were increased, and there
was diffuse moderate hepatocellular swelling with increased amounts of pale,
glassy cytoplasm, mild anisocytosis, occasional binucleate hepatocytes, and
rare single-cell necrosis. (B) Masson trichrome stains of preinfection (left) and
week 194 (right) liver tissue showing evidence of fibrosis (collagen, blue) with
septae lining hepatic sinusoids in tissue collected at 194 weeks.
FIG 4 Immunohistochemical staining of 4x0193 liver tissue for markers of
innate immune response (ISG-15), apoptosis (caspase 3), and cellular prolif-
eration (nuclear Ki67 expression). A marked increase in hepatocellular ISG-15
expression is evident between preinfection liver and tissue collected at 8 and
especially 194 weeks. Caspase 3 expression is also increased, especially in asso-
ciation with collections of lymphoid cells. Multiple, single, and paired Ki-67-
positive nuclei are evident at 194 weeks, consistent with increased hepatocel-
lular proliferation.
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10-fold decrease in RNA accumulation at 48 h (Fig. 2C) with re-
duced expression of HCV core protein (Fig. 2D). Infectious virus
yields were also reduced by at least 50-fold (Fig. 2A). Collectively,
these and earlier results demonstrating the importance of the
S2204I mutation for replication in cell culture (11) identify this
residue in NS5A (NS5A residue 232) as pivotal in determining the
contrasting abilities of wild-type versus cell culture-adapted geno-
type 1a HCV to replicate in vivo versus within cultured Huh-7
cells. It is likely that the delayed kinetic of H77.2 viremia in 4x0193
was caused by a severe restriction imposed by S2204I on H77S.2
replication in vivo that was partially reversed by the change at 2204
from Ile to Thr and then more fully reversed by complete rever-
sion to the wild-type Ser residue by week 62 (Table 3).
The reversion of the cell culture adaptation mutation Q1067R
(NS3 residue 41) to the wild-type Gln residue by week 8 (Fig. 6A
and Table 3) suggests it also impairs fitness in vivo. However,
mutagenesis studies demonstrated that it is quite different from
S2204I. Loss of the mutation had no effect on RNA replication in
transfected cells (H77S.2/R1067Q) (Fig. 2C) but instead signifi-
cantly enhanced the yield of infectious virus (Fig. 2A). Thus, this
mutation is likely to reduce fitness both in vivo and in vitro. Al-
though our early studies showed it to promote replication of sub-
genomic HCV RNA replicons in Huh-7 cells, this effect appears to
be lost or otherwise made redundant within genome-length
H77S.2 RNA containing other adaptive mutations (see reference
18 for additional details).
We also studied an additional mutation in NS3, G1202E (NS3
residue 177), identified at week 8 in 4x0193 (Table 3). This residue
is Glu in most genotype 1 viruses but is Gly in wild-type H77c as
well as H77S.2 virus. Previous studies show that a Glu-to-Gly sub-
stitution at this position promotes replication of the genotype 1b
Con1 virus in Huh-7 cells while possibly impairing its replication
in chimpanzees (38). Altering the wild-type G1202 residue in
H77S.2 to Glu resulted in a moderate decrease in RNA replication
as well as infectious virus production following electroporation of
the RNA into cells (Fig. 2C). Thus, the H77S.2 G1202 residue may
serve as a natural adaptive mutation that enhances H77S.2 repli-
cation in Huh-7 cells but reduces its fitness in chimpanzees. Con-
sistent with the latter notion, G1202E substitutions have also been
noted in two chimpanzees infected by intrahepatic inoculation of
synthetic H77c RNA in other studies (Table 3) (39).
Replication phenotype of H77S.2 versus wild-type H77c vi-
rus in humanized Alb-uPA/SCID mice. Although the prolonged
interval between intravenous inoculation of H77S.2 virus and the
appearance of viremia in 4x0193 (Fig. 1C) likely reflects the need
for reversion of cell culture-adaptive mutations as suggested
above, it is also possible that prior immunologic priming during
the brief, self-limited HJ3-5 infection suppressed the initial repli-
cation of the virus. In an effort to distinguish between these pos-
sibilities, we assessed replication phenotypes in the absence of an
immune response in immunodeficient Alb-uPa/SCID mice with
chimeric human livers (36). None of 6 animals became infected
after being inoculated intravenously with 1.5 105 FFU H77S.2/
R1067Q (H77S.3) virus produced in cell culture. We also at-
tempted infection by direct intrahepatic inoculation of synthetic
RNA. Of 4 animals challenged with the wild-type H77c RNA (22),
only 1 developed an infection marked by significant and sustained
viremia, while the other 3 did not show convincing evidence of
infection (Fig. 7, left). This lack of infection likely reflects a com-
bination of RNase activity in the liver and failure of the synthetic
RNA to enter human hepatocytes in the chimeric liver. Intrahe-
patic inoculation of HCV RNA has also failed to initiate infection
in the chimpanzee in some experiments (38). Similarly, only 1 of 3
animals inoculated intrahepatically with H77S.2 RNA showed de-
finitive evidence of infection (Fig. 7, right). Thus, the infection
“take rate” was similar following inoculation of either wild-type or
cell culture-adapted H77S.2 RNA. There were marked differences
in the course of the infection in the two infected animals, however.
Wild-type H77c RNA produced high-grade viremia (up to 1.3 
106 GE/ml) that persisted for over 80 days, whereas the maximum
H77S.2 viremia was 1,000-fold less (1.5  103 GE/ml) and present
for only 28 days (Fig. 7). These data are consistent with the H77S.2
FIG 5 Innate immune response to sequential HJ3-5 and H77S.2 infections in chimpanzee 4x0193. (A) Serum cytokine levels measured by Luminex assay during
the period of HJ3-5 infection and the first 26 weeks of persistent H77S.2 infection: (top) IL-12, IP-10, and MIP-1 serum levels; (bottom) inflammasome-related
serum cytokine levels of IL-1 and IL-18. (B) Intrahepatic ISG mRNA transcript levels measured by real-time qRT-PCR 2, 26, 79, and 194 weeks after intravenous
inoculation of cell culture-derived H77S.2 virus. (C) Intrahepatic IFN transcripts 2 and 194 weeks after infection with H77S.2 virus: IFN-, IL-28 (IFN-2 and
-3), IL-29 (IFN-1), and IFN-	.
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RNA having a markedly attenuated replication phenotype in vivo
compared to the wild-type H77c genome.
Structural context of amino acid substitutions occurring
during H77S.2 infection in 4x0193. Experimental high-resolu-
tion models exist for the three-dimensional structures of sev-
eral nonstructural HCV proteins, including the NS2 protease,
the NS3 protease-helicase, NS5A domain I, and the NS5B
RNA-dependent RNA polymerase (31–34, 40). To gain insight
into the selective forces driving evolution of the H77S.2 ge-
nome in 4x0193, we assessed the structural context of substi-
tutions occurring within these nonstructural proteins. We con-
sidered it likely that amino acid substitutions influencing
interactions with host cell proteins would be located at or near
the solvent-accessible surface of the nonstructural proteins. In
contrast, mutations reflecting escape from T cell recognition of
peptide epitopes presented on class I molecules may be more
randomly distributed between surface-exposed and nonex-
posed residues. Surprisingly, each of the nonsynonymous sub-
stitutions occurring within domains of the nonstructural proteins
for which structural information exists involved amino acid resi-
dues that were at least partially surface exposed.
No substitutions were identified within the catalytic domain of
the NS2/NS3 protease for which a crystallographic structure exists
(40). However, 8 nonsynonymous substitutions occurred in the
NS3 protease and helicase domains (Table 3). Each of these 8
substitutions involved a surface-exposed residue in the three-di-
mensional structure of this bifunctional complex from PDB entry
1CU1 (31). Four substitutions involved residues located within or
near a predicted protein-protein interaction site, I1098 (NS3-72),
G1202 (NS3-176), I568 (NS3-542), and I1641 (NS3-615), while
A1266 (NS3-240) is in close proximity to the ATP-binding site
(Fig. 8). The 3 remaining substitutions are not located near pre-
FIG 6 Substitutions arising in the H77S.2 genome during persistent infection of 4x0193. (A) The viral genome with nucleotide and amino acid coordinates is
shown in the middle of the figure with synonymous (above) and nonsynonymous (below) substitutions identified at 8, 62, and 194 weeks after infection. Each
triangular symbol represents a change from the base or amino acid residue present at the preceding time point; the sequence present at each position is shown
at week 194, with intermediate changes shown in a single-letter entry next to the relevant symbol. Changes in the 6 cell culture-adaptive mutations are shown in
boldface; all had reverted to the wild-type H77c sequence by week 194. Table 3 provides a list of additional substitutions identified at week 250. (B) Rates of
nonsynonymous and synonymous nucleotide substitutions within the polyprotein coding region of H77S.2 virus shown by period following infection. Rates were
calculated as the number of substitutions per nonsynonymous and synonymous sites by the method of Nei and Gojobori (30). The overall rate of nucleotide
substitutions (shown as all substitutions per base per year) declined over the 250-week period. (C) Ratio of the rates of nonsynonymous to synonymous
substitutions (dN/dS) by period following infection.
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TABLE 3 Changes in H77S.2 virus sequence during persistent infection in chimpanzee 4x0193h
Cell culture-adaptive mutation





8 62 194 250 8 62 194 250
362b,c U¡C U¡C
1226 C¡U
1250 C¡A C¡A C¡A E1 303 D¡E D¡E D¡E
1435 U¡C E1 365 V¡A
1513 A¡C A¡C A¡C E2 391 N¡T N¡T N¡T
1515 G¡A G¡A G¡A E2 392 A¡T A¡T A¡T
1673b,e,f A¡U A¡U A¡U E2 444b,e,f Q¡H Q¡H Q¡H
1754 U¡C U¡C
AAC¡GAC (N476D) 1767 G¡A G¡A G¡A E2 476 D¡N D¡N D¡N
1780b U¡C E2 480b L¡P
1853b C¡U C¡U




2163 A¡U A¡U E2 608 M¡L M¡L
2180 U¡C
2218 U¡C U¡C U¡C E2 626 I¡T I¡T I¡T
2468 C¡U C¡U
2583 U¡C
2661–2 UU¡CU UU¡GC UU¡GC UU¡GC p7 774 F¡L F¡A F¡A F¡A
2801 C¡U
2989 C¡U C¡U C¡U NS2 883 T¡I T¡I T¡I
3047c U¡C U¡C
3116 G¡A G¡A
CAA¡CGA (Q1067R) 3541–2 GA¡AA GA¡AA GA¡AG GA¡AG NS3p 1067 R¡Q R¡Q R¡Q R¡Q
3569 G¡A G¡A G¡A
3633 A¡G A¡G A¡G A¡G NS3p 1098 I¡V I¡V I¡V I¡V
3946b,c G¡A G¡A G¡A G¡A NS3p 1202b,c G¡E G¡E G¡E G¡E
4064 G¡C
4138 C¡U C¡U C¡U NS3h 1266 A¡V A¡V A¡V







5045 A¡G A¡G NS3h 1568 I¡M I¡M
5147 A¡G A¡G
5210 U¡C
5261 A¡C A¡G A¡G
GTC¡ATC (V1655I) 5262 A¡G A¡G A¡G NS3h 1641 I¡V I¡V I¡V
5304 A¡G A¡G NS3h 1655 I¡V I¡V
AAG¡AGG (K1691R) 5413 G¡A G¡A G¡A NS4A 1691 R¡K R¡K R¡K
5420 A¡G
5480 G¡A
5575c U¡A NS4B 1745c,g V¡D
5587 C¡U NS4B 1749 A¡V
5617b,c U¡C U¡C NS4B 1759b,c V¡A V¡A
5759 C¡U
5810 C¡U C¡U C¡U
5819 U¡C U¡C
5846 U¡C U¡C
(Continued on following page)
Yi et al.
3686 jvi.asm.org Journal of Virology
dicted protein-protein interaction sites. These include Q1067R
(NS3-41), which is close to the protease active site, and I1655V
(NS3-629), which is close to the site of scission and part of the
natural substrate for NS3 proteolysis. Both are reversions of cell
culture-adaptive mutations in the H77S.2 clone. Interestingly,
G1202 and I1655, as well as S1358 (NS3-332), which represents a
change from the wild-type H77c sequence to the consensus geno-
type 1a sequence (39), are also located within known T cell
epitopes that are potentially relevant in this animal (see the fol-
lowing section).
Two nonsynonymous substitutions occurred within that part
of NS5A domain I for which structural models are available. Both
R2040K (NS5A-68, representing a reversion of the K2040R cell
culture-adaptive mutation) (Table 3) and S2118 (NS5A-146) in-
volve surface-exposed residues within the proposed homodimer
interface (Fig. 9A, left) in PDB entry 3FQQ (32). S2118 is imme-
TABLE 3 (Continued)
Cell culture-adaptive mutation





8 62 194 250 8 62 194 250
5888 G¡A G¡A
6026 U¡C U¡C U¡C
6275 G¡A G¡A
6330 G¡A G¡A G¡A NS5A d1 1997 A¡T A¡T A¡T
AAA¡AGA (K2040R) 6460 G¡A G¡A NS5A d1 2040 R¡K R¡K
6693c U¡C NS5A d1 2118c S¡P
AGC¡ATC (S2204I) 6951–2 AU¡AC AU¡UC AU¡UC AU¡UC NS5A d1/2 2204 I¡T I¡S I¡S I¡S
7083b,f A¡G A¡G NS5A d2 2248b,f N¡D N¡D
7226 C¡U C¡U
7359b,c C¡G C¡G NS5A d3 2340b,c L¡V L¡V
7361c A¡G
7394 U¡C U¡C
7417–8b GC¡AG GC¡AC GC¡AC NS5A d3 2359b G¡E G¡D G¡D
7575f G¡A G¡A NS5A d3 2412b,c A¡T A¡T
7586c A¡G A¡G A¡G
7797–8 GA¡AG GA¡AG GA¡AG NS5B 2486d,g D¡S D¡S D¡S
7856 A¡G A¡G A¡G A¡G
7894 A¡G A¡G NS5B 2518 K¡R K¡R
8124 C¡U
8152 U¡A U¡A NS5B 2604 L¡Q L¡Q
8591 G¡A G¡A
8687 U¡C U¡C U¡C
8918 U¡C U¡C U¡C
9194 A¡G
9232 G¡A NS5B 2964 R¡Q
a NS3p, protease domain; NS3h, helicase domain; NS5a domains (d1, d2, and d3) are according to Tellinghuisen et al. (68).
b Identical substitution at this position in chimpanzee 1530 (39).
c Identical substitution at this position in chimpanzee 1564 (39).
d Alternative amino acid substitutions (A2412D, D2486E) are at this position in chimpanzee 1564 (39).
e Identical substitution at this position in chimpanzee 1535 (59).
f Identical substitution at this position in chimpanzee 1536 (59).
g Alternative amino acid substitution (V1745A, D2486E) at this position in chimpanzee 1535 (59).
h Cell culture-adaptive mutations and reversions are shown in boldface; synonymous nucleotide substitutions are shaded.
TABLE 4 Nonsynonymous substitutions occurring within potential class 1 epitopes in H77S.2 virus during persistent infection in chimpanzee
4x0193
Protein Amino acid substitution(s) Chimpanzee class I Chimpanzee epitope sequence Mutation direction
E2 L546M B1301 TRPPLGNWFb Away
E2 M608L Not mappeda ITPRCMVDYPYRLWHYPC Toward
NS3h S1358P B1301 VPHPNIEEV Toward
NS3h I1568M Not mappeda FTGLTHIDAHFLSQTKQS Away
NS3h I1641V, I1655V Not mappeda ITKYIMTCMSADLEIV Away
NS5A d1 A1997T B0101 KTWLKAKLM Away
NS5B K2518R A0301 CSLTPPHSAK Away
a Epitopes were identified using CD8 T cell lines, but class I molecules responsible for presentation were not mapped.
b Residue undergoing substitution is underlined.
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diately adjacent to E2120 (NS5A-148), a residue that plays a key
role in homodimer formation (32). An alternate dimer structure,
with the dimerization domain on the opposing side of the mono-
mer, was proposed in an earlier model in PDB entry 1ZH1 (33),
but the monomer folds are similar for both (Fig. 9A, right). In
both proposed dimeric structures, the membrane association of
NS5A is mediated through the N-terminal part of the monomer,
and a role for K2040 in modulating membrane association is con-
sistent with both models. All 4 nonsynonymous substitutions oc-
curring in the NS5B polymerase also involve surface-accessible
residues in the structural model proposed in PDB entry 2XI2 (34)
(Fig. 9B). L2604 (NS5B-184) is located within the putative RNA-
binding groove, while K2518 (NS5B-98) is close to the NTP chan-
nel. Both are located within predicted protein-protein interaction
sites (Fig. 9B). The two remaining residues, 2486D (NS5B-66) and
2964R (NS5B-544), are close to the RNA-binding groove but not
associated with predicted sites of protein-protein interactions.
It is remarkable that all of the nonsynonymous substitutions
identified in protein domains for which structural models are
available involved surface-accessible residues. To assess whether
this could be due simply to chance, we compared the surface ac-
cessibility of the amino acid residues at which substitutions oc-
curred to that of residues included in the model structures (see
Materials and Methods). The difference was statistically signifi-
cant for NS5B alone (P  0.021 by nonparametric Mann-Whitney
U test) and even more significant when all substitutions were con-
sidered in the NS3, NS5A, and NS5B structures (P 
 0.002).
Sequence evolution and predicted CD8 T cell escape. Im-
mune selection pressure has generally been considered to be the
dominant force driving increased nonsynonymous substitutions
in HCV genomes during the acute phase of infection (7). Nonsyn-
onymous substitutions in nonstructural proteins are concen-
trated in class I epitopes during the first year of infection and then
subside, presumably as CD8 T cell effector functions fail (39, 41).
Because this pattern of substitutions was observed in 4x0193, we
sought to determine whether any amino acid changes fell within
known class I epitopes. The Immune Epitope Database (http:
//www.iedb.org) and Los Alamos National Laboratory HCV
Database (http://hcv.lanl.gov) were searched for class I epitopes
matched to the H77S.2 challenge sequence and presented by the
Patr class I A*0201, A*0301, B*0101, and B*1301 of chimpanzee
4x0193. An additional 6 epitopes presented by these chimpanzee
class I molecules but not yet deposited in public databases (C.
Walker, unpublished data) were also included. Of the 36 nonsyn-
onymous substitutions observed over 5 years of follow-up, 8 (ap-
proximately 22% of the total) were located in epitopes known to
be presented by class I molecules expressed by this animal (Table
4). Of these 8, 4 (L546M, I1568M, I1641V, and A1997T) appeared
before week 62, a time frame associated with the highest rate of
nonsynonymous substitution (Fig. 6B) and CD8 T cell selection
pressure (39). S1358P occurred in the same time frame, but this
substitution reconstitutes an epitope rather than providing escape
from one. As indicated above, Pro is the consensus amino acid at
position 1358 in genotype 1a virus. The three remaining nonsyn-
onymous changes (M608L, I1655V, and K2518R) occurred some-
time after week 62 but before week 194. Escape mutations in HCV
class I epitopes have been documented in chimpanzees 2 years
after infection (42), but other selective forces cannot be excluded
for changes that appeared well after chronic infection was estab-
lished. For instance, I1655V represented reversion of a cell cul-
ture-adaptive mutation that facilitated replication of H77S.2 virus
in cell culture.
DISCUSSION
The chimpanzee, Pan troglodytes, is the only animal species other
than Homo sapiens that is naturally fully permissive for HCV in-
fection, and it has served as an exceptionally valuable model of the
infection in humans (28). In the past, experimental infections of
the chimpanzee established hepatitis C (then known as parenter-
ally transmitted non-A, non-B hepatitis) as a distinct disease en-
tity and also provided unique biological samples that facilitated
the identification and molecular cloning of the responsible virus
(43, 44). The chimpanzee model has also played a key role in the
preclinical evaluation of candidate hepatitis C vaccines (45).
However, in recent years the need for the chimpanzee model has
lessened given progress in developing improved cell culture sys-
tems supporting replication of the virus (12, 17, 46, 47), as well as
innovative mouse models that can be infected in vivo (36, 48, 49).
Coupled with the ethical implications of the uniquely close rela-
tionship of chimpanzees to humans, such advances have led to
increasing restrictions on the use of the chimpanzee in hepatitis C
research (25). We report here the 5.5-year follow-up of a chim-
panzee that developed persistent infection following intravenous
challenge with a cell culture-adapted genotype 1a virus produced
in Huh-7.5 cells. This study is unique in that, to our knowledge,
this is the only chimpanzee to have sustained a persistent infection
after challenge with virus produced in cell culture. All other chim-
panzee infections with HCV produced in cell culture (HCVcc)
were with viruses possessing genomes derived in whole or in part
from the genotype 2a JFH1 virus and expressing JFH1 replicase
proteins (12, 16, 50). All of these infections were self-limited, with
no demonstrable liver injury (Table 1). In contrast, 4x0193, in-
fected with H77S.2 virus, experienced long-term viral persistence
(288 weeks at the last health check) associated with continued
elevation of serum ALT activity, strong intrahepatic innate im-
mune responses, and histologic evidence of hepatic inflammation
and fibrosis, typical features of chronic hepatitis C in humans.
Several aspects of the infection in chimpanzee 4x0193 are par-
ticularly notable. First, the animal became persistently infected
when challenged with H77S.2 2 years after a brief, transient infec-
tion with HJ3-5 virus, an H77/JFH1 chimera expressing structural
proteins that differ at only 2 residues (one each in E1 and E2) from
H77S.2. Although infection with HJ3-5 virus did not result in
seroconversion in the ELISA or detectable levels of serum neutral-
izing antibodies, the H77S.2 challenge resulted in an immediate,
FIG 7 HCV viremia in Alb-uPa/SCID mice inoculated intrahepatically with
synthetic wild-type H77c RNA (left) or H77S.2 RNA (right). Despite compa-
rable infection take rates (1 of 4 versus 1 of 3 animals), H77c viremia peaked at
1,000-fold higher levels than H77S.2 RNA.
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anamnestic antibody response (Fig. 1C). The potential for rein-
fection of chimpanzees following clearance of an initial HCV in-
fection has been clearly established previously (51). However,
prior infection typically results in a robust CD8 T cell response
on rechallenge that limits the extent and duration of secondary
infections (52, 53). It is noteworthy that prior HJ3-5 virus infec-
tion did not prevent an unfit, cell culture-adapted HCV inoculum
(see below) from establishing persistent infection and chronic
hepatitis.
A second notable feature of the infection in 4x0193 is the lengthy
delay this animal experienced prior to the onset of viremia. This is
unusual. All 3 chimpanzees infected by intrahepatic inoculation of
clonal wild-type H77 RNA were viremic within a week (54, 55). It is
possible that immunologic priming during the preceding HJ3-5 in-
fection suppressed early H77S.2 viremia (52). However, we believe it
more likely that the 6 cell culture-adaptive mutations in H77S.2 con-
ferred a strong, negative effect on intrahepatic replication, and
that detectable levels of viremia required the evolution of a more
fit virus within the liver. The S2204I mutation in NS5A seems
particularly likely to have contributed to inefficient initial replica-
FIG 8 Structural context of mutations occurring in the NS3 protein of H77S.2 virus during persistent infection of chimpanzee 4x0193, modeled on the structure
of the bifunctional protease-helicase of genotype 1b BK strain of HCV (PDB entry 1CU1). Residues at which mutations were identified (Table 1) are labeled
according to the H77S.2 sequence with the authentic BK residue shown in parentheses. Solvent-accessible surfaces of these residues are shaded in yellow, while
the overall surface of the structure is colored according to ProMate output, with red shading representing high probability and blue shading a low probability that
each surface residue contributes to a protein-protein interaction site (see Materials and Methods). Protein-protein interaction sites predicted by ProMate are
shown encircled by a dashed red line. The single mutation identified in NS4A (R1691K, a reversion of a cell culture-adaptive mutation) occurs at residue 34 of
NS4A and is located just outside the ordered structure of the NS4A peptide strand in the NS3/4A complex.
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tion of the virus in vivo, as it plays a key role in the cell culture
adaptation of H77S (11). It is also in close proximity (in the linear
peptide sequence of NS5A) to a cell culture-adaptive mutation,
S2197P, that limited the capacity of genotype 1b Con1 RNA to
replicate in chimpanzees in a previous study (38). This earlier
study examined a set of mutations that enhance replication of
Con1 RNA replicons but that do not provide for significant infec-
tious virus production in cell culture. Thus, chimpanzees were
challenged by intrahepatic RNA injection (38) rather than inocu-
lation with infectious, cell culture-produced virus. Nonetheless,
despite these methodologic differences, both NS5A mutations
(S2197 in Con1 and S2204I in H77S.2) appear to similarly restrict
replication in vivo. The S2204I mutation in H77S.2 was partially
reverted by 8 weeks after challenge (I2204T mutation) (Table 3),
shortly after viremia was first detected (Fig. 1C). The I2204T sub-
stitution was also present in a cDNA fragment of HCV RNA re-
covered from the liver biopsy specimen taken at 2 weeks. Thus,
this NS5A mutation appears to have reverted very early in the
course of infection, consistent with substantial selective pressure
acting at this site in the genome. A second mutation in the NS3
protease of H77S.2, Q1067R, had also reverted by 8 weeks
(Table 3). It was originally found to promote replication of a sub-
genomic replicon, but it is not required for optimal replication of
the complete H77S.2 genome in cell culture (11, 17, 18) (Fig. 2).
Further evidence for a primary role for S2204I rather than
Q1067R in impeding replication in vivo is provided by the absence
of infection in 6 SCID-Alb/uPA mice inoculated intravenously
with H77S.3 virus. This virus contains all of the cell culture-adap-
tive mutations in H77S.2 (including S2204I) with the exception of
Q1067R. S2204 and Q1067 are both very highly conserved, how-
ever, and are present in 99% of genotype 1a viruses. Inefficient
replication of H77S.2 virus in vivo may have been due to both of
these cell culture-adaptive mutations.
The absence of detectable viremia, even with the very sensitive
TMA assay, for a month following infection of 4x0193 with
H77S.2 virus (Fig. 1C) is relevant to recent clinical trials of DAAs
where some subjects were found to relapse after completing treat-
ment with mericitabine or sofosbuvir, potent nucleosides or nu-
cleotide inhibitors of the NS5B polymerase that effectively sup-
pressed replication (56, 57). S282T is a key mutation that confers
resistance to these compounds, and its absence following the re-
appearance of viremia has been interpreted as indicative of the
FIG 9 Structural context of mutations occurring in domain I of NS5A and NS5B protein of H77S.2 virus during persistent infection of chimpanzee 4x0193. (A)
NS5A residues involved in mutations are highlighted in yellow on the surface of domain I of the protein from the genotype 1b Con1 strain of HCV (PDB entry
3FQQ) (left). Residues with key roles in homodimer formation are highlighted in green (32). Also shown is an imposition of the monomer structures proposed
in alternate structural models (right), with the peptide backbone from PDB entry 2FQQ (32) shown in gray and that from PDB entry 1ZH1 (33) in cyan. The side
chain of K68 is highlighted in yellow in both structures. Side chains of residues presumed to be closest to the membrane surface in PDB entry 1ZH1 (33) are shown
as stick models. The structural superposition was calculated using the jCE/jFATCAT Structure Alignment Server v2.6 (http://source.rcsb.org/jfatcatserver/index
.jsp) with jCE algorithm, PDB entry 3FQQ chain A, and 1ZH1 chain A. (B) Residues involved in nonsynonymous mutations in the NS5B protein are highlighted
in a structural model of the polymerase from wild-type H77c virus (PDB entry 2XI2). Residues are labeled and colored as described in the legend to Fig. 8.
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absence of virologic resistance (56, 57). Importantly, because the
S282T mutation impacts the active site of the polymerase, S282T
viruses are very impaired in replication. The course of the infec-
tion in 4x0193 demonstrates that a nonfit virus can replicate for
weeks within the liver in the absence of detectable viremia, and
that when the virus does eventually mutate to a more fit pheno-
type the mutations that had made it unfit may no longer be de-
tectable. Thus, caution must be taken in inferring the absence of
virologic resistance from the absence of detectable resistance-as-
sociated variants following the reappearance of virus in relapsing
patients.
Each of the 6 cell culture-adaptive mutations in H77S.2 virus
eventually reverted to the original wild-type sequence during per-
sistent infection in 4x0193 (Table 3). This is strong evidence that
mutations conferring enhanced replication in Huh-7 cells reduce
fitness in the liver and are negatively selected in vivo. Importantly,
the involved nonstructural protein residues are highly conserved
among genotype 1a viruses and are present among 216 sequences
downloaded from the European database (58) at the following
rates: Q1067, 99.1%; V1655, 97.7%; K1691, 98.1%; K2040, 97.7%;
and S2204, 100%. The mechanism(s) underlying the conservation
of these residues is uncertain. The cell culture-adaptive mutations
are likely to promote replication in cell culture by optimizing
functionally important interactions between nonstructural viral
proteins and host cell factors present in Huh-7 cells but not hepa-
tocytes in vivo. Such a model is consistent with the surface location
of the 3 cell culture-adaptive mutations that are positioned within
nonstructural protein domains for which structural models exist:
Q1067R (NS3 protease), V1655I (NS3 helicase), and K2040R
(NS5A domain I) (Fig. 8 and 9). However, there may have been
multiple factors driving the selection of the revertants in 4x0193,
as reversion of the cell culture-adaptive mutation V1655I (I1655V
mutation first noted at week 62) (Table 3) would also provide for
escape from a putative T cell epitope (Table 4).
The rate with which nonsynonymous substitutions accumu-
lated during the first 8 weeks of infection (5.79 103 substitu-
tions/site/year) was almost twice that observed previously during
the first 26 weeks of infection initiated by intrahepatic inocula-
tion of wild-type H77 RNA in two other chimpanzees (2.59 to
2.88 103 substitutions/site/year) (59). It is not clear, however,
whether the method used to estimate these rates in the earlier
study was the same as that used here for 4x0193 (see Materials and
Methods). As in previous studies involving long-term follow-up
of wild-type H77 infection in chimpanzees (39, 59), the ratio of
nonsynonymous to synonymous substitutions fell after the first
year of infection, with the rate of all observed substitutions reach-
ing a plateau of 1.26  103 substitutions/base/year by 250 weeks
(Fig. 6). In addition to the reversion of cell culture-adaptive mu-
tations in 4x0193, it is likely that the higher rate of nonsynony-
mous substitutions during the first year of infection (Fig. 6B and
C) reflects the emergence of T cell escape mutations. While we
sought to identify substitutions affecting known T cell epitopes of
relevance to the Patr type of this particular animal (Table 4), our
analysis of potential escape mutations almost certainly underesti-
mated the impact of CD8 T cell selection pressure on evolution
of the H77S.2 virus. The repertoire of known epitopes presented
by Patr class I A*0201, A*0301, B*0101, and B*1301 molecules is
still quite small. Because of substantial variability in the pattern of
epitope dominance among HCV-infected individuals, it is likely
that 4x0193 exerted immune pressure against other class I-pre-
sented epitopes that have yet to be identified. Our analysis also
does not account for compensatory mutations that occur outside
epitopes to offset any fitness cost of immune escape to virus rep-
lication (60).
B cell pressure may have also contributed to the evolution of
H77S.2 virus in this animal. A strong anamnestic antibody re-
sponse was noted in the anti-HCV ELISA within 1 week of intra-
venous challenge with H77S.2 virus despite the absence of
viremia, and neutralizing antibodies were detected as early as week
2. Two nonsynonymous substitutions in E2 (N391T and A392T)
are located within the central part of the hypervariable region I
(HVR1) domain of this envelope protein that is known to interact
with antibodies (61). Although HVR1 displays a lower rate of
nonsynonymous substitutions in infected chimpanzees than in
humans (62), it is reasonable to surmise that the changes at N391
and A392 have occurred in response to the selective pressure of
antibodies. Q444H is also located within a domain of E2 (residues
434 to 446) that is bound by neutralizing antibodies and also in-
teracts with a cellular receptor for HCV, CD81 (63).
Altogether, of 36 nonsynonymous substitutions occurring
during the first 250 weeks of infection in 4x0193, 6 were reversions
of engineered cell culture-adaptive mutations, while 8 can be re-
lated to potential T cell escape (one of which is also a reversion of
a cell culture-adaptive mutation) and 3 may represent B cell es-
cape (Table 3). Interestingly, for 10 of the remaining 20 nonsyn-
onymous substitutions, identical or very similar substitutions
have been observed in other chimpanzees that became persistently
infected with HCV following intrahepatic inoculation of wild-
type H77c RNA (39, 59) (Table 3). In 4 instances, similar or iden-
tical substitutions were observed in animals inoculated with RNA
from an independently constructed molecular clone (54, 59),
arguing against these common changes arising from errors in con-
struction of consensus clones. These common changes could rep-
resent reversions of archived T cell escape mutations that were
selected for in patient H, the source of H77c virus, or perhaps the
source from which patient H acquired the infection. Alternatively,
it is possible that they are chimpanzee-adaptive mutations for
which no direct evidence yet exists.
Despite the slow start to the infection in 4x0193, this animal
developed impressive evidence of liver disease in parallel with an
increasing viremia. The serum ALT became persistently elevated
above baseline (Fig. 1A), and liver biopsy specimens showed pro-
gressively increasing inflammatory infiltrates with fibrosis (Fig.
3). Serum IP-10 (CXCL10), dramatically elevated transiently with
the earlier HJ3-5 virus infection, became reelevated and persisted
(Fig. 5A). In both infections, IP-10 elevations occurred in parallel
but approximately 1 to 2 weeks after the increase in serum HCV
RNA. This was matched by substantial upregulation of IP-10 and
other ISG transcripts within the liver (Fig. 5B), as observed in
many human subjects with chronic hepatitis C (64). Importantly,
there was good congruence between the increases in intrahepatic
IP-10 and ISG-15 transcript abundance (Fig. 5B), IP-10 protein
detected in serum (Fig. 5A), and ISG-15 protein expression in the
liver (Fig. 4). This suggests that the translation of these innate
immune effector proteins is not significantly blocked by protein
kinase R activation, as suggested by Garaigorta et al. (65). While
serum IL-1, recently proposed as a central regulator of hepatic
inflammation in chronic hepatitis C (66), was also elevated in
H77S.2 infection, the expression of this cytokine did not correlate
with viremia, ALT, or hepatic inflammation. It may have reflected
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a nonspecific response to the cell culture-derived inoculum. Col-
lectively, these data suggest a striking difference in the pathogenic
potential of H77S.2 virus and JFH1-related viruses produced in
cell culture (Table 1). They also reaffirm the ability of the chim-
panzee to closely model many aspects of hepatitis C in humans
and suggest that this particular animal should be considered for
treatment with direct-acting antiviral therapy.
As with many studies of HCV infection in chimpanzees, the
conclusions that can be drawn from this study are tempered by the
use of one or only a small number of animals. Nonetheless, as
described above, important conclusions can be drawn from the
pattern of H77S.2 infection observed in animal 4x0193. Given an
increasing variety of systems in which different aspects of HCV
can be studied, it is unlikely that a study such as this would be
contemplated today. Future efforts to characterize the in vivo rep-
lication potential of HCV produced in cell culture will likely de-
pend on the use of genetically humanized or xenotransplanted
murine models (49, 67).
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